Baxter International Inc. (BAX) 56.91 0.07

Baxter International, Inc.
(BAX) 56.91 0.07

Last Trade:	56.91	Day Range:	56.81 - 57.05
Trade Time:	11:02AM	52wk Range:	47.5518 - 62.50
Prev. Close:	56.84	Market Cap:	32.09B
Open:	57.05	Div Yield:	2.22
Volume:	594712	PE:	150
EPS:	3.88

The Latest On BAX

Top Performing Health Care Stocks in January 2/1/12 6:32am

Baxter Announces FDA Approval of Expanded Indication for TISSEEL for General Hemostasis in Surgery 1/30/12 9:00am

Piper Jaffray Lowers PT on Baxter International to $65 1/27/12 10:26am

Morgan Keegan Reports Baxter to Initiate Second PIII Alzheimer's Disease Trial 1/24/12 9:52am

Morgan Stanley Maintains Overweight Rating on Baxter International 1/24/12 7:05am

From Earlier: Baxter to Initiate Second Phase III Trial Studying GAMMAGARD LIQUID for the Treatment of Alzheimer's Disease 1/24/12 6:43am

J.P. Morgan Maintains Overweight Rating on Baxter Intl 1/17/12 7:02am

Feltl and Company Downgrades Synovis Life Technologies to Sell 1/11/12 12:24pm

JP Morgan Reiterates Overweight, $60 Target on Baxter International 1/11/12 8:42am

Baxter Submits Application for FDA Approval of GAMMAGARD LIQUID to Treat Multifocal Motor Neuropathy 1/9/12 9:00am

Baxter Initiates Phase I Clinical Trial of Longer-Acting Recombinant FVIII Treatment for Hemophilia A 1/5/12 8:35am

Baxter Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital 1/4/12 5:12pm

Top Performing Health Care Stocks in January 2/1/12

Baxter Announces FDA Approval of Expanded Indication for TISSEEL for General Hemostasis in Surgery 1/30/12

Piper Jaffray Lowers PT on Baxter International to $65 1/27/12

Morgan Keegan Reports Baxter to Initiate Second PIII Alzheimer's Disease Trial 1/24/12

Morgan Stanley Maintains Overweight Rating on Baxter International 1/24/12

From Earlier: Baxter to Initiate Second Phase III Trial Studying GAMMAGARD LIQUID for the Treatment of Alzheimer's Disease 1/24/12

J.P. Morgan Maintains Overweight Rating on Baxter Intl 1/17/12

Feltl and Company Downgrades Synovis Life Technologies to Sell 1/11/12

JP Morgan Reiterates Overweight, $60 Target on Baxter International 1/11/12

Baxter Submits Application for FDA Approval of GAMMAGARD LIQUID to Treat Multifocal Motor Neuropathy 1/9/12

Baxter Initiates Phase I Clinical Trial of Longer-Acting Recombinant FVIII Treatment for Hemophilia A 1/5/12

Baxter Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital 1/4/12

Top Performing Health Care Stocks in January 2/1/12

Benzinga's M&A Chatter for Tuesday December 13, 2011 12/13/11

Piper Jaffray Rates Baxter Overweight; $69 PT 11/30/11

Earnings Preview: Baxter International's EPS, Revenue Expected to Rise 10/17/11

Volatility Crush 10-12-2011 10/12/11

Financial Breakfast: Morning News Summary for September 27, 2011 9/27/11

U of Colorado Opens Cord Blood Bank: What About Cord Blood Stocks 9/7/11

Top 4 Large-Cap Stocks In The Medical Instruments & Supplies Industry With The Highest Revenue 8/29/11

News Summary for July 20, 2011 7/21/11

Stocks to Watch for 07/8/11: Fresh 52 Week Highs and Lows 7/7/11

Stocks to Watch for 07/7/11: Fresh 52 Week Highs and Lows 7/6/11

Piper Jaffray Lowers PT on Baxter International to $65 1/27/12

Morgan Keegan Reports Baxter to Initiate Second PIII Alzheimer's Disease Trial 1/24/12

Morgan Stanley Maintains Overweight Rating on Baxter International 1/24/12

J.P. Morgan Maintains Overweight Rating on Baxter Intl 1/17/12

Feltl and Company Downgrades Synovis Life Technologies to Sell 1/11/12

JP Morgan Reiterates Overweight, $60 Target on Baxter International 1/11/12

RBC Capital Downgrades Baxter International to Outperform 12/20/11

Piper Jaffray Lowers PT on Baxter International to $66 12/16/11

UPDATE: J.P. Morgan Lowers Price Target on Baxter Intl to $60 12/13/11

JP Morgan Lowers PT on Baxter International to $60 12/13/11

Piper Jaffray Rates Baxter Overweight; $69 PT 11/30/11

UPDATE: Morgan Keegan Lowers Price Target on Baxter International to $60 11/29/11

Trade BAX
NOW!

Partner Headlines

Baxter International near Key Resistance Area 2/13/12

Earnings Scorecard: Baxter - Analyst Blog 2/7/12

Becton Beats, Profit Drops - Analyst Blog 2/7/12

Earnings Preview: Becton, Dickinson - Analyst Blog 2/6/12

Baxter Int'l 1/26/12

Earnings Preview: Baxter - Analyst Blog 1/24/12

Apple, Top Manufacturers Lead S&P 100 Earnings Due 1/22/12

Biosimilar Drug Era Dawns 1/20/12

Biotechs Cut Biosimilar Deals As FDA Carves Path 1/20/12

Integra's Prelim Results Disappoint - Analyst Blog 1/6/12

Stocks That Are Cheaper Than When Bill Frels Bought Them 1/4/12

The Zacks Analyst Blog Highlights: JA Solar Holdings, China Sunergy, Coach, Baxter and Becton, Dickinson and Co. - Press Releases 1/3/12

Press Releases

Baxter Announces FDA Approval of Expanded Indication for TISSEEL [Fibrin Sealant] for General Hemostasis in Surgery 1/30/12 Business Wire Story

Baxter Reports Sales and EPS for Fourth Quarter and Full-Year 2011 in Line with Guidance 1/27/12 Business Wire Story

Mt. Ascutney Hospital and Health Center in Vermont Receives Prestigious $100,000 Foster G. McGaw Prize for Excellence in Community Service 1/24/12 Business Wire Story

Baxter to Initiate Second Phase III Trial Studying GAMMAGARD LIQUID (IGIV) for the Treatment of Alzheimer's Disease 1/23/12 Business Wire Story

Baxter Appoints Jean-Luc Butel as President, International 1/9/12 Business Wire Story

Baxter Submits Application for FDA Approval of GAMMAGARD LIQUID to Treat Multifocal Motor Neuropathy, a Degenerative Neurological Disorder 1/9/12 Business Wire Story

Baxter Initiates Phase I Clinical Trial of Longer-Acting Recombinant FVIII Treatment for Hemophilia A 1/5/12 Business Wire Story

Baxter Recommends Shareholders Reject "Mini-Tender" Offer by TRC Capital 1/4/12 Business Wire Story

Baxter and Momenta Announce Collaboration to Develop and Commercialize Follow-On Biologics 12/22/11 Business Wire Story

Baxter to Present at the 30th Annual J.P. Morgan Health Care Conference 12/21/11 Business Wire Story

The Law Firm of Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of Synovis Life Technologies Inc. in Connection with the Sale of the Company to Baxter International Inc. 12/15/11 Business Wire Story

Baxter Responds to Patient Needs in Aftermath of Thailand Floods 12/15/11 Business Wire Story

Get the latest BAX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Baxter International, Inc. stock price.

Baxter International, Inc. by YCharts